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BACKGROUND: Socioeconomic inequalities in survival were observed for many cancers in England during 1981–1999. The NHS
Cancer Plan (2000) aimed to improve survival and reduce these inequalities. This study examines trends in the deprivation gap in
cancer survival after implementation of the Plan.
MATERIALS AND METHODS: We examined relative survival among adults diagnosed with 1 of 21 common cancers in England during
1996–2006, followed up to 31 December 2007. Three periods were defined: 1996–2000 (before the Cancer Plan), 2001–2003
(initialisation) and 2004–2006 (implementation). We estimated the difference in survival between the most deprived and most
affluent groups (deprivation gap) at 1 and 3 years after diagnosis, and the change in the deprivation gap both within and between
these periods.
RESULTS: Survival improved for most cancers, but inequalities in survival were still wide for many cancers in 2006. Only the deprivation
gap in 1-year survival narrowed slightly over time. A majority of the socioeconomic disparities in survival occurred soon after a cancer
diagnosis, regardless of the cancer prognosis.
CONCLUSION: The recently observed reduction in the deprivation gap was minor and limited to 1-year survival, suggesting that, so far,
the Cancer Plan has little effect on those inequalities. Our findings highlight that earlier diagnosis and rapid access to optimal
treatment should be ensured for all socioeconomic groups.
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Socioeconomic inequalities in survival have been reported for
most adult cancers in England and Wales. Among adults diagnosed
during 1981–1990, 5-year survival for those living in the most
deprived areas was significantly lower than for those in the most
affluent areas for 44 of 47 different cancers (Coleman et al, 1999).
During the 1990s, cancer survival improved significantly for
almost all the common cancers. For many cancers, however,
survival improved more for patients living in affluent areas than
for those living in deprived areas. As a result, the deficit in survival
between rich and poor (the ‘deprivation gap’) widened during this
time (Coleman et al, 2004). Such observations suggest that
deprived patients may not have benefited equally from advances
in early diagnosis and treatment.
The NHS Cancer Plan for England was published in late 2000
(Department of Health, 2000). It was designed to improve
prevention, early diagnosis and screening, and to provide optimal
treatment for all patients, thus improving survival and quality of
life. One of the main aims of the Cancer Plan was to tackle
inequalities in cancer survival for people from deprived or less
affluent backgrounds. Inequalities in cancer mortality under 75
years of age between the most deprived 20% of Local Authority
Districts (Spearhead LADs) and England as a whole decreased by
11.3% between the baseline period 1995–1997 and 2004–2006,
already more than the 6% reduction that had been targeted for
2009–2011 (Department of Health, 2003, 2007).
Overall survival for adults diagnosed with one of the common
cancers in England up to 1999 remains lower than in many
comparable European countries (Berrino et al, 2007), but it has
improved against the highest survival in Europe, and the number
of deaths within 5 years of survival that would be avoidable in
England if the highest level of survival in Europe had been
achieved decreased slightly during the 1990s (Abdel-Rahman et al,
2009). Recent observations also suggest a modest acceleration of
the previous upward trend in short-term survival in England since
implementation of the NHS Cancer Plan, for patients diagnosed
during 2001–2006 and followed up to 2007 (Rachet et al, 2009).
Given the longstanding inequalities in cancer survival in England
since the 1970s, however, we have examined the effectiveness of the
Cancer Plan in reducing socioeconomic inequalities in survival.
We used national data on all cancer patients diagnosed in
England during the 11 years 1996–2006 and followed up to the end
of 2007. We estimated the survival of patients diagnosed in three
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scalendar periods, defined in relation to the NHS Cancer Plan:
1996–2000 (5 years; before the Cancer Plan), 2001–2003 (3 years;
initialisation) and 2004–2006 (3 years; implementation). We
examined relative survival in five categories of socioeconomic
deprivation and the ‘deprivation gap’ in survival between the most
deprived and most affluent groups. Changes in the deprivation gap
between successive calendar periods before, during and after
the introduction of the Cancer Plan provide a quantitative measure
of any change in the survival deficit, and an early indication
of whether the plan is achieving its goal of reducing inequalities
in survival.
MATERIALS AND METHODS
The data, study design and analytical tools have been described
(Rachet et al, 2009). Briefly, we examined the data for all adults
(15–99 years) diagnosed in England during 1996–2006 with 1 of
21 common primary malignant neoplasms that represent 90.7%
of all cancers. In all, 6% of cases were excluded from analysis
because the patient’s survival was either zero or unknown (tumour
registered from a death certificate only), and 1.4% because of
unknown vital status or sex, duplicate registration, synchronous
tumours, or invalid dates or date sequences. Patients who had
a previous cancer of the same organ or tissue at any time since
1971 were also excluded. In all, we were able to include some
2.2 million cancer patients in the analyses, 92.5% of those eligible
(Table 1).
The National Cancer Registry contains no information regarding
the socioeconomic status of individual cancer patients. Instead, an
ecological measure of deprivation was used, on the basis of the
socioeconomic characteristics of the Lower Super-Output Area
(LSOA) in which each patient was resident at the time of diagnosis.
The income domain score of the Indices of Multiple Deprivation
(IMD2004) was categorised into five groups by quintiles of
the 34378 LSOAs (mean population 1500) in England. Cancer
patients were assigned to the deprivation category of their LSOA
(from 1 ‘most affluent’ to 5 ‘most deprived’), using the postcode of
residence at diagnosis and a combined historic file, covering the
whole study period, of 2.1 million unique full postcodes, each
linked to a complete set of contemporary geographic area codes.
Statistical analysis
We estimated relative survival for each of the five deprivation
categories, for each cancer and each sex, and by year or period of
diagnosis. Relative survival is the ratio of the observed probability
of survival and the probability that would have been expected if the
cancer patients had only experienced the normal (background)
mortality of the general population in which they live, given the
same distribution of factors such as age, sex, geographical area,
calendar period and deprivation. Relative survival is the standard
approach to estimating population-based survival. It does not rely
on accurate reporting of the cause of death, and it enables
estimation of long-term survival from cancer, when competing
causes of death become more important. It can be interpreted as
survival from cancer after adjustment for other causes of death.
Background mortality was derived from population life tables.
Mortality rates vary widely between socioeconomic groups and
geographic regions in England, so we constructed life tables by
single year of age (0–99 years), sex, deprivation category and
Government Office Region for 1991, 2001 and 2005, using the mid-
year population estimates and the mean annual number of death
registrations during the 3 years centred on the index year. Death
records were assigned to deprivation categories through the
postcode and LSOA in the same way as the cancer cases, so that
background mortality was precisely matched to the deprivation
categories of the cancer patients. Linear interpolation between the
census-based life tables was used to obtain life tables for other
calendar years in the period 1996–2005 (Cancer Research UK
Cancer Survival Group, 2004). Life tables for 2006 and 2007 could
not be constructed, because the relevant data (deaths during
2007–2008) were unavailable. Life tables for 2005 were used for
those years, without extrapolation.
Table 1 Number of patients eligible for survival analysis, exclusions (%) and no. (%) of patients included: 21 common cancers, England, adults
(15–99 years) diagnosed 1996–2006 and followed up to 2007
Exclusions Patients included
Malignancy Eligible for analyses Death certificate only
a Zero survival
b Other
c No. %
Oesophagus 66479 4.0 1.8 0.5 62359 93.8
Stomach 82101 4.9 2.6 0.5 75467 91.9
Colon 199149 4.5 2.4 1.6 182244 91.5
Rectum 117410 2.4 1.3 0.6 112319 95.7
Pancreas 66322 11.1 5.1 0.4 55327 83.4
Larynx (M) 16154 2.1 0.8 0.8 15537 96.2
Lung 343065 7.0 3.8 0.8 303422 88.4
Melanoma 69921 1.0 0.2 1.6 67963 97.2
Breast (F) 386627 2.2 0.8 3.6 361105 93.4
Cervix 27219 1.7 0.8 1.2 26200 96.3
Uterus 55579 2.2 0.9 0.7 53484 96.2
Ovary 61986 4.7 2.2 0.7 57253 92.4
Prostate 280790 3.4 1.1 0.9 265753 94.6
Testis 17683 0.4 0.2 2.2 17210 97.3
Kidney 59381 5.7 3.1 0.9 53609 90.3
Bladder 102927 2.9 1.1 0.9 97908 95.1
Brain 36630 4.9 2.0 1.0 33717 92.0
Hodgkin0s disease 12880 0.8 0.6 1.2 12548 97.4
Non-Hodgkin lymphoma 87685 3.1 2.1 1.2 82082 93.6
Myeloma 34379 5.1 2.3 0.7 31593 91.9
Leukaemia 62197 7.2 3.1 0.8 55260 88.8
Total 2186564 4.1 2.0 1.4 2022360 92.5
aRegistration from a death certificate only.
bDate of diagnosis same as date of death, but record not flagged as a ‘death certificate only’ registration.
cAged 100 years or over at
diagnosis, vital status or sex unknown, sex-site error, invalid dates, duplicate registration, synchronous tumours or a previous cancer of the same organ or tissue at some time
since 1971.
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sTo account for the rapid change in cancer-related mortality in
the period immediately after a cancer diagnosis, survival
probabilities were estimated at short (e.g., 1-month) intervals in
the first few months after diagnosis, then at progressively longer
intervals up to 10 years after diagnosis, using the maximum-
likelihood approach for individual data (Este `ve et al, 1990). We
report the cumulative probabilities of relative survival at 1 and 3
years after diagnosis.
All patients were followed up for at least 1 year, so the cohort
approach was applied throughout to estimate year-on-year trends
in 1-year survival. For longer-term survival, patients were grouped
into three calendar periods of diagnosis (1996–2000, 2001–2003
and 2004–2006). For the first two periods, 3-year survival was
derived from a cohort design. The shorter period of follow-up data
available for patients diagnosed during 2004–2006 meant that only
the complete approach was available for analysis. Short-term
predictions of survival were made for patients diagnosed in 2007
using the hybrid approach (Brenner and Rachet, 2004).
A variance-weighted linear regression was fitted, incorporating
all deprivation-specific relative survival estimates, thus allowing
changes in survival to vary by deprivation group and calendar
period. The deprivation gap in survival was quantified as the
simple difference (%) between fitted relative survival in the most
deprived and most affluent groups within each calendar period.
A negative value indicates that survival in the most deprived group is
lower than survival in the most affluent group. Similarly, a negative
value for any change in the deprivation gap means that it widened
between successive calendar periods. All analyses were carried out in
Stata 10 (StataCorp, College Station, TX, USA), including relative
survival analyses with the publicly available Stata programme strel
(Cancer Research UK Cancer Survival Group, 2006).
RESULTS
One-year relative survival
Table 2 summarises the 1-year survival results for each cancer. As
an example, Figure 1 shows the year-on-year variation in 1-year
survival for rectal cancer among men and women in the most
affluent and the most deprived groups in England. For men
diagnosed with rectal cancer during 1996–2000 (before the plan),
1-year survival improved among both affluent and deprived
groups, but more quickly for the affluent, and the deprivation
gap widened (Figure 1; equivalent figures for each cancer in web-
appendix). The rate of improvement slowed for men diagnosed
during 2001–2003 (initialisation), especially for the most deprived,
and the deprivation gap in 1-year survival widened further. For
men diagnosed during 2004–2006 (implementation), 1-year
survival rose more rapidly among the most deprived men than
the most affluent, and the deprivation gap narrowed. One-year
survival among all men in England rose from 79.0% in 1996 to
82.6% in 2006, and the deprivation gap narrowed from –8.9% to
–6.8% over this period (Table 2). The gap widened slightly by
 0.1% a year during 1996–2000 and 2001–2003 but narrowed by
1.1% a year during 2004–2006. Among women, the reduction in
deprivation gap during 2001–2003 reflects a transient reduction in
1-year survival among the most affluent group.
We summarise here the detailed results for 17 cancers in men
and 18 in women, 35 cancer-sex combinations in all (Table 2).
Results are presented for three cancers in men only (larynx,
prostate and testis) and for four cancers in women only (breast,
cervix, uterus and ovary).
For patients diagnosed in 1996, 1-year survival was lower in the
most deprived group than in the most affluent group (negative
deprivation gap) for 34 of the 35 cancer-sex combinations, and for
27 of these, the deprivation gap was statistically significant at 5%
(Table 2). Survival from brain tumours was slightly higher among
men in the most deprived group (þ0.6%). For patients diagnosed
in 2006, the deprivation gap in 1-year survival was again negative
for all but three cancer-sex combinations: Hodgkin’s disease in
men (þ7.4%, Po0.05) and women (þ2.0%) and myeloma in
women (þ0.4%).
For patients diagnosed during 1996–2000 (before the Cancer
Plan), the deprivation gap narrowed (positive annual change) for
five cancers in men and eight in women, but no reduction was
more rapid than 1% per year (Table 2). The deprivation gap
widened (negative annual change) for most of the 22 remaining
cancer-sex combinations. The annual change was 4 1% a year
for cancers of the oesophagus (women) and ovary, and 4 0.5%
for four cancers in men and one in women.
For 2001–2003, the deprivation gap in 1-year survival narrowed
for 11 of 17 cancers in men and 11 of 18 cancers in women: the rate
of improvement was 1% or more per year for laryngeal cancer and
Hodgkin’s disease in men, and for malignancies of the ovary and
brain in women. For other cancers, the deprivation gap was
unchanged or became wider, but only for non-Hodgkin lymphoma
in women did the gap widen by 40.5% a year.
For 2004–2006, the period beginning 3 years after implementa-
tion of the Cancer Plan, inequalities in 1-year survival narrowed
for seven cancers in men and 12 in women, and for six
malignancies the deprivation gap decreased by 1% or more a
year: rectum, brain and Hodgkin’s disease in men and pancreas,
non-Hodgkin lymphoma and the leukaemias in women.
Overall, between 1996 and 2006, the deprivation gap in 1-year
survival narrowed for 8 cancers in men and 13 in women, but
widened for 9 cancers in men and 5 in women.
For four malignancies in women (stomach, ovary, myeloma and
the leukaemias) and for Hodgkin’s disease in men, the deprivation
gap in 1-year survival decreased slightly but steadily during both
the 3-year periods we had designated after introduction of the NHS
Cancer Plan (2000–2003, 2004–2006). For three other malignan-
cies in women (breast, kidney and melanoma) and for non-
Hodgkin lymphoma in men, the deprivation gap decreased slightly
but consistently over the entire period 1996–2006. A majority of
the larger falls in the deprivation gap in any given period coincided
with a decrease or a plateau in the trend in survival among the
most affluent patients: Hodgkin’s and non-Hodgkin lymphoma in
both sexes and brain tumours in women (web-figures).
We chose to summarise trends in short-term survival and in the
deprivation gap in survival for two broad groups of malignancies,
defined by 1-year relative survival in England in 1996 of o40%
(‘poor prognosis’ group: oesophagus, stomach, pancreas, lung and
brain) or 460% (‘good prognosis’ group: the other 16 cancers).
The patients in each group were analysed together, not separated
by site or type of cancer. One-year survival trends were estimated
for good-prognosis and poor-prognosis cancers, by sex, depriva-
tion and year of diagnosis. Overall, 1-year survival rose in both
sexes, both for good-prognosis and poor-prognosis cancers, within
each of the three periods 1996–2000, 2001–2003 and 2004–2006,
and for all deprivation categories (Table 3, Figure 2A: only the
most affluent and the most deprived groups are plotted).
For cancers with a good prognosis, the deprivation gap during
2004–2006 was around  6t o 8% in both sexes. This is wider
than for cancers with a poor prognosis, around  2t o 3%
(Figure 2B). Both for good-prognosis and poor-prognosis cancers,
the deprivation gap in 1-year survival widened during 1996–2000,
but then narrowed during 2001–2003 (Figure 2B). For good-
prognosis cancers in women, the deprivation gap in 1-year survival
continued to narrow more quickly during 2004–2006, but it was
stable for poor-prognosis cancers. For men, no obvious pattern
was observed in 2004–2006, for both good-prognosis and poor-
prognosis cancers.
Patterns of 1-year survival by deprivation and over time were
also analysed with non-linear regression models, using cubic
regression splines. In spite of some differences for the less
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sTable 2 Deprivation gap in 1-year relative survival (%) by sex in 1996 and 2006, and annual change in the deprivation gap in survival within period of
diagnosis: adults (15–99 years) diagnosed 1996–2006 and followed up to 2007, 21 common cancers, England
Calendar period of diagnosis (NHS Cancer Plan periodisation)
Period 1 Period 2 Period 3
1996 2006
1996–2000
(Pre-Cancer Plan)
2001–2003
(Initialisation)
2004–2006
(Implementation)
Malignancy
Survival in
most affluent
Deprivation
gap (%)
a
Survival in
most affluent
Deprivation
gap (%)
a
Annual change in
deprivation gap
b 95% CI
Annual change in
deprivation gap
b 95% CI
Annual change in
deprivation gap
b 95% CI
Oesophagus
Men 30.0  4.8* 43.9  8.4**  0.4  1.2, 0.4 0.0  1.1, 1.1  0.3  2.3, 1.6
Women 25.3  0.9 38.2  7.4*  1.2  2.2,  0.1 0.9  0.6, 2.4  1.1  3.7, 1.6
Stomach
Men 34.9  5.0** 43.3  4.4* 0.0  0.8, 0.7  0.1  1.2, 1.0 0.4  1.5, 2.4
Women 33.6  4.8* 40.4  3.7  0.2  1.2, 0.8 0.2  1.2, 1.7 0.5  2.2, 3.2
Colon
Men 72.1  8.0** 76.6  7.7** 0.2  0.4, 0.8  0.3  1.1, 0.4 0.2  1.1, 1.4
Women 69.2  7.2** 75.4  10.6**  0.2  0.8, 0.4  0.2  1.0, 0.6  0.4  1.7, 0.9
Rectum
Men 79.0  8.9** 82.6  6.8**  0.1  0.8, 0.5  0.1  0.9, 0.7 1.1  0.2, 2.5
Women 77.7  8.7** 82.2  9.4** 0.0  0.8, 0.8 0.6  0.4, 1.7  1.1  2.9, 0.6
Pancreas
Men 14.9  2.5 19.4  4.9*  0.7  1.4, 0.1 0.7  0.3, 1.7  0.4  2.1, 1.4
Women 14.2  3.9* 17.5  2.6 0.1  0.6, 0.8  0.5  1.5, 0.5 1.0  0.8, 2.7
Larynx
Men 89.2  6.6* 90.0  7.4*  0.5  1.6, 0.5 1.2  0.2, 2.6  1.0  3.5, 1.5
Lung
Men 24.8  3.3** 27.4  1.6 0.2  0.2, 0.5 0.3  0.2, 0.8  0.3  1.1, 0.6
Women 24.7  1.5 30.9  3.1*  0.2  0.6, 0.3  0.1  0.8, 0.5 0.0  1.0, 1.1
Melanoma
Men 95.6  3.5* 97.1  2.9*  0.1  0.8, 0.5 0.6  0.2, 1.3  0.3  1.5, 0.8
Women 97.8  1.4 98.0  0.4 0.0  0.4, 0.4 0.1  0.4, 0.6 0.2  0.5, 1.0
Breast
Women 95.8  4.0** 97.8  2.6** 0.1 0.0, 0.3 0.1  0.1, 0.3 0.1  0.2, 0.4
Cervix
Women 88.9  7.7** 90.3  6.0* 0.4  0.3, 1.1  0.3  1.4, 0.7 0.3  1.6, 2.1
Uterus
Women 88.9  4.1** 92.8  3.8*  0.4  1.0, 0.2 0.7 0.0, 1.4  0.1  1.2, 1.1
Ovary
Women 67.9  4.6* 71.9  3.4  1.0  1.7,  0.3 1.1 0.2, 2.1 0.8  0.8, 2.5
Prostate
Men 89.6  3.6** 97.0  2.9**  0.2  0.5, 0.0 0.6 0.3, 0.9  0.2  0.7, 0.2
Testis
Men 98.9  1.5 99.5  1.7* 0.2  0.2, 0.6  0.5  1.0, 0.1 0.2  0.7, 1.1
Kidney
Men 68.0  6.9** 71.8  7.0*  0.1  1.0, 0.9 0.3  0.9, 1.5  0.3  2.3, 1.8
Women 63.8  6.6* 70.9  4.2 0.2  1.0, 1.5 0.0  1.6, 1.6 0.3  2.3, 3.0
Bladder
Men 86.1  7.0** 80.2  7.1** 0.0  0.5, 0.6 0.7  0.2, 1.5  1.1  2.7, 0.4
Women 77.1  9.9* 71.6  14.2** 0.2  0.8, 1.3 0.0  1.5, 1.5  2.0  4.6, 0.6
Brain
Men 30.2 0.6 36.4  1.5  0.6  1.7, 0.6  0.4  2.0, 1.1 1.1  1.6, 3.8
Women 31.6  7.6* 30.6  1.0 0.4  0.9, 1.8 1.0  0.8, 2.9  0.2  3.4, 2.9
Hodgkin0s
disease
Men 92.8  1.3 86.5 7.4*  0.6  1.8, 0.6 1.1  0.7, 2.9 2.6  0.6, 5.8
Women 94.7  6.1* 86.4 2.0 0.9  0.3, 2.2  0.1  2.0, 1.7 0.9  2.7, 4.5
Non-hodgkin
lymphoma
Men 73.2  7.8** 77.6  5.7* 0.2  0.6, 1.0 0.2  0.9, 1.2 0.1  1.6, 1.8
Women 75.0  10.7** 77.7  4.3* 0.5  0.3, 1.4  0.7  1.8, 0.4 2.0 0.2, 3.9
Myeloma
Men 67.1  6.1* 71.5  9.0*  0.2  1.5, 1.2  0.1  1.8, 1.7  0.5  3.6, 2.5
Women 64.0  4.2 68.5 0.4  0.2  1.6, 1.3 0.0  1.9, 2.0 1.9  1.5, 5.2
Leukaemia
Men 66.9  4.2* 65.2  6.6*  0.5  1.5, 0.5 0.2  1.1, 1.5  0.1  2.4, 2.2
Women 63.1  5.1* 61.1  1.2  0.6  1.8, 0.5 0.7  0.8, 2.3 1.5  1.3, 4.2
Abbreviation: CI¼confidence interval.
aAbsolute difference (%) between relative survival in the most deprived and the most affluent groups, derived from variance-weighted
regression. A negative value means that survival in the most deprived group is lower than survival in the most affluent group.
bMean absolute change (%) in the deprivation gap in
survival within the period. A neqative value means that the deprivation gap has widened. *Po0.05; **Po0.001.
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conclusions were identical.
Three-year relative survival
A significant deficit in 3-year survival among patients in the more
deprived groups was observed for 33 of the 35 cancer-sex
combinations examined during 1996–2000, for 26 in 2001–2003
and for 24 among patients diagnosed during 2004–2006
(web-table, equivalent to Table 2). Only for brain tumours in
men was the deprivation gap in 3-year survival consistently
positive (higher survival in more deprived groups) throughout the
period 1996–2006. Short-term predictions of 3-year survival for
patients diagnosed in 2007 suggest that the number of cancer-sex
combinations with a significant deprivation gap will decrease
further to 18 of 35. However, these changes mainly reflect
a decrease in statistical power rather than a narrowing of the
deprivation gap in survival, because the data sets for 2001–2003
and 2004–2006 (3 years) are 40% smaller than for 1996–2000
(5 years). The overwhelming pattern of lower survival in more
deprived groups for almost all cancers seems more persuasive than
whether individual estimates of the deprivation gap are statistically
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Figure 1 One-year relative survival for rectal cancer for the most deprived and most affluent groups, by sex, England 1996–2006. Lines are the regression
plots fitted in a single model, which comprises every survival estimate by deprivation and calendar year (see text); dashed line: most deprived group; plain
line: most affluent group.
Table 3 Deprivation gap in 1-year and 3-year relative survival (%), by sex and calendar period of diagnosis, and trends in deprivation gap (%) in survival,
adults (15–99 years) diagnosed 1996–2006 and followed up to 2007: cancers with ‘good’ and ‘poor’ prognosis, England
Calendar period of diagnosis (NHS Cancer Plan periodisation)
Period 1 Period 2 Period 3
1996–2000
(Pre-Cancer Plan)
2001–2003
(Initialisation)
2004–2006
(Implementation)
Change in deprivation
gap since previous period
b
Time since
diagnosis
Survival in
most affluent
Deprivation
gap (%)
a
Survival in
most affluent
Deprivation
gap (%)
a
Survival in
most affluent
Deprivation
gap (%)
a 2001–2003 95% CI 2004–2006 95% CI
Prognostic group
One year
Good prognosis
c
Men 85.2  7.6** 86.2  6.9** 87.7  6.6** 0.7 0.1, 1.3 0.3  0.7, 1.2
Women 87.5  7.6** 88.1  6.9** 89.1  5.8** 0.7 0.1, 1.2 1.1 0.2, 2.0
Poor prognosis
d
Men 29.4  3.9** 30.5  3.4** 32.0  3.8** 0.6  0.4, 1.6  0.5  2.2, 1.3
Women 28.2  3.0** 29.7  2.9** 30.3  2.6* 0.1  1.1, 1.3 0.3  1.8. 2.4
Three years
Good prognosis
c
Men 69.3  8.6** 73.4  9.4** 75.9  8.8**  0.7  1.6, 0.2 0.5  0.5, 1.5
Women 74.2  9.1** 76.2  9.0** 78.0  7.6** 0.1  0.6, 0.9 1.3 0.4, 2.2
Poor prognosis
d
Men 11.0  1.9** 11.8  2.0** 12.2  1.7**  0.1  0.9, 0.7 0.3  0.7, 1.3
Women 11.1  1.8** 12.0  1.2* 11.9  0.8 0.6  0.4, 1.6 0.4  0.8, 1.7
Abbreviation: CI¼confidence interval.
aAbsolute difference (%) between relative survival in the most deprived and most affluent groups, derived from variance-weighted
regression. A negative value means that survival in the most deprived group is lower than survival in the most affluent group.
bMean absolute change (%) in the deprivation gap in
survival since the previous period. A neqative value means that the deprivation gap has widened.
c‘Good-prognosis’ cancers are: bladder, breast, cervix, colon, Hodgkin’s disease,
kidney, larynx, leukaemia, melanoma, myeloma, Non-Hodgkin lymphoma, ovary, prostate, rectum, testis and uterus.
d‘Poor-prognosis’ cancers are: brain, lung, oesophagus,
pancreas and stomach. *Po0.05; **Po0.001.
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ssignificant. Thus, a negative deprivation gap in 3-year survival was
observed for 34 of 35 cancer-sex combinations in 1996–1999 and
for 31 in 2004–2006, and is predicted for 28 of 35 cancer-sex
combinations for patients diagnosed in 2007. Only for a few
cancers did the deprivation gap itself actually narrow over time,
confirming the overall lack of improvement.
We also examined changes over time in the deprivation gap in
3-year survival for cancers that we defined as having a ‘good’ or
‘poor’ 1-year prognosis (60% or above and under 40%, respec-
tively, for patients diagnosed in England in 1996). There was no
obvious pattern in either group (Table 3). In particular, in spite of
the expected ceiling effect for cancers for which survival was over
80%, the narrowing of the deprivation gap was not more marked
for cancers with a good prognosis than for those with a poor
prognosis.
Excess hazard of death
The excess hazard of death among cancer patients, relative to the
general population, is naturally much higher in the first month
after diagnosis than in the third year after diagnosis, and much
higher for cancers with a ‘poor’ 1-year prognosis than for those
with a ‘good’ prognosis (Figure 3). The excess hazard is also much
higher for patients in the most deprived group than for those in the
most affluent group. Strikingly, however, while there is a large
socioeconomic difference in the excess hazard of death in the
period shortly after diagnosis, as exemplified for the first month in
Figure 3, no such difference in the excess hazard is observed
during the third year after diagnosis.
This pattern was present throughout the period 1996–2006, in
both sexes. The excess hazard of death decreased steadily both for
affluent and deprived patients, and for cancers with both ‘good’
and ‘poor’ prognosis, but these trends were not accompanied by a
narrowing of the deprivation gap.
DISCUSSION
This study updates the effect of socioeconomic deprivation on
cancer survival in England to the end of 2007. It includes over 2
million patients diagnosed with one of 21 common cancers in the
11-year period spanning the introduction of the first comprehen-
sive cancer plan in 2000.
Survival for patients in the most deprived group was
significantly lower than among the most affluent patients for most
cancers in both sexes, extending observations made for patients
diagnosed during 1971–1990 (Coleman et al, 1999) and 1986–1999
(Coleman et al, 2004). The overall pattern of lower survival in the
more deprived groups has changed very little over the three
successive calendar periods that we defined a priori in relation to
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Figure 2 (A) Trends in 1-year relative survival for the most deprived and most affluent groups, by cancer prognosis, England 1996–2006. Lines are the
regression plots fitted in a single model, which comprises every survival estimate by deprivation and calendar year (see text); dashed line: most deprived
group; plain line: most affluent group. (B) Trends in deprivation gap in 1-year relative survival, by cancer prognosis, England 1996–2006. Deprivation gap is
the simple difference in 1-year relative survival between the most deprived group and the most affluent group. Lines are the regression plots fitted in a single
model, which comprises every survival estimate by deprivation and calendar year (see text).
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sthe NHS Cancer Plan. The socioeconomic gradient in 1-year
survival often remained the same, or even widened for a few
cancers, although the gap narrowed for several cancers of good
prognosis.
Socioeconomic inequalities in cancer survival in England and
Wales are well documented. Similar disparities have been reported
in Scotland (Shack et al, 2007), Denmark (Dalton et al, 2008), the
United States and, to a lesser extent, in Canada (Gorey et al, 2009),
and in other countries (Kogevinas and Porta, 1997; Woods et al,
2006). With a few exceptions, most of the socioeconomic deficits in
survival occur shortly after diagnosis, and they tend to attenuate or
disappear with time since diagnosis (Rachet et al, 2008). The
findings reported here confirm persistent and wide socioeconomic
inequalities in the excess hazard of death in the period
immediately after a cancer diagnosis. They indicate that more
attention should be given to earlier diagnosis and prompt access to
optimal treatment for all socioeconomic groups. In 2003, the
Tackling Health Inequalities strategy set out to improve access to
cancer services by ensuring that, by 2005, all cancer patients were
treated within a month of diagnosis and within 2 months of urgent
referral (Department of Health, 2003), thus reaffirming the waiting
time targets initialised in the Cancer Plan. Earlier diagnosis also
became a central goal of the National Awareness and Early
Diagnosis Initiative in 2008 (Richards, 2009), which seeks to raise
symptom awareness and encourage early presentation.
The origins of the deprivation gap in cancer survival are still not
clear: the roles played by tumour, patient and health-care system
factors, respectively, remain controversial (Woods et al, 2006;
Rachet et al, 2008). The inequalities are not simply explained by
more advanced stage at diagnosis among deprived groups
(Schrijvers et al, 1995; Jeffreys et al, 2006) or, for colorectal
cancers at least, by more frequent or more severe co-morbidity
(Shack, 2009).
Socioeconomic differences in diagnosis, investigation and
treatments have also been identified in the United Kingdom, both
qualitatively and quantitatively (Dixon et al, 2003). In the United
States, both socioeconomic and ethnic disparities in cancer
survival have been reported (Singh et al, 2004). Ethnicity, often
considered a proxy for deprivation, is strongly associated with the
type of health insurance (McDavid et al, 2003). The survival deficit
for colorectal cancer among US Blacks was not apparent when
health care was provided within the equal-access Veterans
Administration system (Rabeneck et al, 2003). It is more
surprising that inequalities in access to the health-care system
have been reported within universal-access health-care systems,
whether centrally funded, as in the United Kingdom, or insurance
based. For example, in Canada, lower socioeconomic status was
associated with higher mortality after stroke and both reduced
access to some health services (Kapral et al, 2002) and treatment at
low-volume hospitals (Saposnik et al, 2008). In England, a
population-based study showed that deprived patients with rectal
cancer were more likely than affluent patients to undergo
abdomino-perineal resection rather than anterior resection, even
after controlling for Duke’s stage (Morris et al, 2008). By contrast,
no socioeconomic disparity in colorectal cancer survival was
observed among patients in a large clinical trial in which, by
definition, every patient of a given arm received the same
treatment (Nur et al, 2008).
These strands of evidence suggest that health-care system
factors do have a major role in inequalities in survival, over and
above tumour and patient factors.
The NHS Cancer Plan of 2000 may have led to quickening
improvements in cancer survival (Rachet et al, 2009), but we have
not yet found strong evidence that implementation of the Cancer
Plan has been followed by a reduction in the deprivation gap in
survival. Without continuing actions targeted at lower socio-
economic groups, however, the inequalities may even become
wider, because survival will increase more rapidly in affluent
groups (Coleman et al, 2004). The greater involvement of general
practitioners in the early detection of cancer may help reduce these
inequalities (Anon, 2009). As set out in the Calman–Hine report
(Expert Advisory Group on Cancer, 1995; Haward, 2006) in 1995,
reducing the geographical and socioeconomic disparities in
outcome still requires action to extend the availability of optimal
health care for all, and to ensure that all patients seek and obtain
access to those services at the earliest possible moment. Further
analyses including more detailed information on the cancers and
their management are essential for understanding the recent and
future patterns in the socioeconomic inequalities in cancer
survival. Such studies have recently become possible since the
linkage between the National Cancer Registry data and Hospital
Episode Statistics data.
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